Navigation Links
ACE Inhibitors For Vascular Disease Patients

Researchers at the Laval University Heart and Lung Institute in Quebec have found that drugs used to treat heart failure also reduced the risk of death, heart attacks// and stroke in people with hardened arteries and hence should be considered in all vascular disease patients.

ACE inhibitors are drugs that lower blood pressure by inhibiting the formation of a chemical that causes arteries in the body to constrict. They are used to treat heart failure.

In an analysis of three major studies, they found that two out of the three studies involving nearly 30,000 people clearly showed such a benefit. The two studies that showed benefits looked at the incidence of heart attacks, stroke and overall deaths from heart disease, while the third study also looked at the incidence of procedures such as angioplasty in patients with atherosclerosis.

Kim Fox, a professor of clinical cardiology at Royal Brompton Hospital in London and a co-author of the report said that ACE inhibitors should be considered in all vascular disease patients.

Dr. Gilles R. Dagenais, a member of the research team said ACE inhibitors should be prescribed "for patients who have coronary heart disease and also atherosclerosis in major arteries, such as those in the brain, if there are no contraindications and if the physician judges there is benefit.”

However, two Italian Cardiologist have argued against the use of ACE inhibitors in such cases pointing to the results of the third study, which was not favorable.

Though the use of ACE inhibitors to reduce risk of vascular disease is debatable, Dr. Gary Francis, Head of the Cleveland Clinic Clinical cardiology section said that the Canadian interpretation was probably correct as it was done by a group highly qualified to do such studies.

Francis said, but "like all meta-analyses, it has some problems. It would be naive to believe that a meta-analysis would have power ov er a randomized, controlled study,"

He also said still "I have a low threshold to go to ACE inhibitors because there is a low price to pay for their benefits. They should be considered for all patients with atherosclerosis.”


'"/>




Related medicine news :

1. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
2. LipB Protein Inhibitors Help To Fight Against TB
3. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
4. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
5. “Don’t fear long haul flights!” Vascular surgeon tells travelrs
6. Drug Effective for Vascular Dementia
7. New Ways To Treat Vascular Birthmarks
8. Is Aricept, the Alzheimer’s Drug Safe to Use against Vascular Dementia
9. Blood Clots, A Common Feature Of Vascular Dementia And Alzheimers
10. Vascular Disease 101: Discovering and Treating Common Diseases of the Veins
11. People Under 60 At Risk Of Premature Peripheral Vascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/25/2017)... ... July 25, 2017 , ... ... it will be exhibiting and providing demos of its smart journaling platform at ... Convention Center in Washington D.C. from August 3-6, 2017. , The APA Annual ...
(Date:7/25/2017)... ... July 25, 2017 , ... Nautilus ... United States, today announced its partnership with financial technology company, Automated Transaction Delivery ... of the solution lies within Hyosung’s superior ATMs, assisted self-service devices and associated ...
(Date:7/25/2017)... ... July 25, 2017 , ... Facing medical needs with a newborn boy this ... of a new benefit for employees that is uncommon in American business: 12 weeks ... supports me and other employees as new parents. It keeps our family life more ...
(Date:7/25/2017)... TX (PRWEB) , ... July 25, 2017 , ... SignatureCare ... emergencies in the Austin, TX area 24 Hours a day. , The ... Austin, TX. , “We’ve been open four months now and things are running ...
(Date:7/24/2017)... JACKSONVILLE, Florida (PRWEB) , ... ... ... Klaproth, Division Marketing Director,      (407) 916-7235, kklaproth(at)robinsmorton(dot)com , Robins ... guests joined together to celebrate the structural topping out of the new ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences Inc. ... to support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing ... a leading Chinese Internet services provider, and joined by ... multiple infectious disease product programs targeting antibiotic resistant infections ... Founded by Dr. Rodolphe Barrangou and ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), today announced that it has reached ... holder and largest shareholder, to modify its existing credit ... to the modification, WAVI agreed to exchange its existing ...
Breaking Medicine Technology: